Dr. Lila W. Hope is an attorney in the Life Sciences practice group and a member of the Cooley Business department. She joined the Firm in 2002 and is a resident in the Palo Alto office.
Her practice focuses on the representation of technology companies, primarily in the life sciences industry. She counsels clients ranging from privately-held companies to Fortune 500 companies. She specializes in transactions involving complex intellectual property, business, operational and legal issues, including strategic partnerships, discovery and option deals, and complex asset purchases. In addition, she counsels clients' management, operational and legal teams on daily legal matters involving grant funding, licensing, supply, distribution, clinical trials, research collaborations and contract services. She is also regularly involved in financing and M&A transactions where she evaluates a company's product rights and operational risks through contract due diligence.
Some of the recent transactions she was involved in include Rigel's collaboration with AstraZeneca on a late stage rheumatoid arthritis product candidate Fostamatinib (valued at $1.2 billion), Reata's collaboration with Abbott on Bardoxolone Methyl (for an upfront and near-term milestone payments of $450 million), Portola's worldwide collaborations with Biogen Idec on autoimmune product candidates, FivePrime's research collaboration with GlaxoSmithKline and product collaboration with Human Genome Sciences, and Gilead's acquisition of Arresto and CV Therapeutics.
Dr. Hope graduated with a J.D. magna cum laude in 2002, from Duke University School of Law, where she was elected to Order of the Coif. At Duke, she was awarded the "Class of 1968 Scholarship." She earned her Ph.D. in Cancer Biology from Stanford University School of Medicine in 1999. As a Stanford Markey Predoctoral Fellow, she characterized a novel tumor susceptibility gene, including its cell cycle-dependent localization, its effects on genome stability and receptor-mediated endocytosis, and its interaction with other gene products. Prior to entering Stanford, she graduated with an M.S. from the Oregon Graduate Institute in 1993, and received her undergraduate education at the University of San Francisco and the University of Science and Technology of China.
Dr. Hope is a member of the State Bar of California and the American Bar Association. She currently serves as director on the Board of Governors for the Stanford University School of Medicine Alumni Association.